Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Current Leases (2019 - 2025)

Historic Current Leases for Celldex Therapeutics (CLDX) over the last 7 years, with Q3 2025 value amounting to $1.6 million.

  • Celldex Therapeutics' Current Leases rose 1261.78% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 1261.78%. This contributed to the annual value of $1.5 million for FY2024, which is 1003.72% down from last year.
  • As of Q3 2025, Celldex Therapeutics' Current Leases stood at $1.6 million, which was up 1261.78% from $1.5 million recorded in Q2 2025.
  • Celldex Therapeutics' Current Leases' 5-year high stood at $1.8 million during Q1 2022, with a 5-year trough of $1.3 million in Q2 2021.
  • For the 5-year period, Celldex Therapeutics' Current Leases averaged around $1.5 million, with its median value being $1.5 million (2025).
  • Within the past 5 years, the most significant YoY rise in Celldex Therapeutics' Current Leases was 3157.5% (2021), while the steepest drop was 1843.04% (2021).
  • Quarter analysis of 5 years shows Celldex Therapeutics' Current Leases stood at $1.7 million in 2021, then dropped by 17.24% to $1.4 million in 2022, then rose by 11.7% to $1.6 million in 2023, then decreased by 10.04% to $1.5 million in 2024, then rose by 6.96% to $1.6 million in 2025.
  • Its last three reported values are $1.6 million in Q3 2025, $1.5 million for Q2 2025, and $1.5 million during Q1 2025.